# Gene Therapy for HER-Positive Cancer (SENTRY-HER2)

> **NCT07192432** · PHASE1,PHASE2 · RECRUITING · sponsor: **Vironexis Biotherapeutics Inc.** · enrollment: 27 (estimated)

## Conditions studied

- HER2 Expressing Solid Tumors

## Interventions

- **GENETIC:** Dose Level 1, VNX-202
- **GENETIC:** Dose Level 2, VNX-202
- **GENETIC:** Dose Level 3, VNX-202
- **GENETIC:** Dose Level 4, VNX-202

## Key facts

- **NCT ID:** NCT07192432
- **Lead sponsor:** Vironexis Biotherapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-18
- **Primary completion:** 2033-09
- **Final completion:** 2033-10
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07192432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07192432, "Gene Therapy for HER-Positive Cancer (SENTRY-HER2)". Retrieved via AI Analytics 2026-08-08 from https://api.ai-analytics.org/clinical/NCT07192432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*